In EpCAM-positive tumors catumaxomab, an antibody that specifically binds EpCAM-positive tumor cells and CD3+ T-lymphocytes, showed an acceptable safety profile and promising treatment efficiency, suggesting EpCAM to be an important target in the therapy of gastric cancer. Here, EPCAM is linked to neoplasm.